Ascendis Pharma director reports initial share and warrant stake

Ascendis Pharma A/S director Imani Siham has filed an initial ownership report showing equity and equity-linked holdings in the company.

Rhea-AI Filing Summary

Ascendis Pharma A/S director Imani Siham has filed an initial ownership report showing equity and equity-linked holdings in the company. The filing lists 2,317 Ordinary Shares held directly. It also shows warrants over 9,160 Ordinary Shares with an exercise price of $102.70 per share, expiring on September 13, 2032.

In addition, Siham holds several grants of restricted stock units, each representing a contingent right to receive one American Depositary Share, which in turn represents one Ordinary Share. According to the footnotes, these restricted stock units vest on March 1, 2027 or in two or three equal annual installments beginning on that date and have no expiration date.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider IMANI SIHAM

Role Director

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants — 9,160 contracts (Direct); Restricted Stock Units — 5,374 contracts (Direct); Ordinary Shares — 2,317 shares (Direct)

Footnotes (6)

1. F1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
2. F2. The warrants vested 25% on September 13, 2023 and thereafter in 36 equal monthly installments.
3. F3. The restricted stock units vest on March 1, 2027 and have no expiration date.
4. F4. Each restricted stock unit represents a contingent right to receive one ADS.
5. F5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
6. F6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing by Imani Siham at Ascendis Pharma (ASND) show?

The Form 3 lists Imani Siham’s initial ownership in Ascendis Pharma, including 2,317 Ordinary Shares, warrants over 9,160 Ordinary Shares, and multiple restricted stock unit awards that convert into American Depositary Shares representing Ordinary Shares under specified vesting schedules.

How many Ascendis Pharma ordinary shares does Imani Siham directly hold on this Form 3?

The filing reports direct ownership of 2,317 Ordinary Shares. This is separate from warrants and restricted stock units, which are rights to receive additional shares in the future based on vesting and, for warrants, payment of the stated exercise price.

What warrants are reported by Imani Siham in the Ascendis Pharma (ASND) Form 3?

The Form 3 shows warrants linked to 9,160 Ordinary Shares with an exercise price of $102.70 per share and an expiration date of September 13, 2032. Footnotes state these warrants vested 25% on September 13, 2023 and continue vesting in 36 equal monthly installments.

How are restricted stock units structured in this Ascendis Pharma Form 3?

Each restricted stock unit represents a contingent right to receive one American Depositary Share, and each ADS represents one Ordinary Share. Footnotes explain that some RSUs vest fully on March 1, 2027, while others vest in two or three equal annual installments starting that date.

Does the Ascendis Pharma (ASND) Form 3 indicate any insider buying or selling by Imani Siham?

The Form 3 is an initial ownership report and lists existing holdings rather than recent trades. Transaction codes are shown as unknown, and the summary data indicates no categorized buys, sells, exercises, gifts, or tax-withholding events associated with this filing.

What is the significance of ADSs in Imani Siham’s Ascendis Pharma holdings?

The footnotes clarify that holdings include American Depositary Shares, with each ADS representing one Ordinary Share. Restricted stock units convert into ADSs upon vesting, so ADSs function as the form in which equity awards ultimately deliver exposure to Ascendis Pharma’s Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:14 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

IMANI SIHAM

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	2,317	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	09/13/2032	Ordinary Shares	9,160	$102.7	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	1,374	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	2,070	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	1,930	(4)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants vested 25% on September 13, 2023 and thereafter in 36 equal monthly installments.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Siham Imani	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)